Evonik is transforming its Health Care business, focusing on core growth areas like APIs and drug delivery.
It will discontinue keto acid production in Hanau by 2025, affecting 260 jobs, while exploring options for its keto and pharma amino acid sites in Ham and Wuming.
The company aims to support affected employees and drive innovation in life sciences.